This is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month DAPT in subjects at HBR undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (The XIENCE family stent systems include commercially approved XIENCE Xpedition Everolimus Eluting Coronary Stent System (EECSS), XIENCE Alpine EECSS or XIENCE PROX EECSS [OUS {Outside of United States} only]) of coronary drug-eluting stents. Approximately 2,000 subjects from approximately 150 sites globally will be enrolled, with at least 50% of subjects in the United States (US). Eligibility of P2Y12 receptor inhibitor discontinuation will be assessed at 3-month follow-up. Subjects who are free from myocardial infarction (MI), repeat coronary revascularization, stroke, or stent thrombosis (ARC definite/probable) within 3 months after stenting and have been compliant with 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days are considered as "3-month clear", and will discontinue P2Y12 receptor inhibitor and continued with aspirin monotherapy after 3-month follow-up. All registered subjects will be followed at 3, 6 and 12 months post index procedure. The data collected from this study will be compared with the historical control of HBR subjects.